See more : Colibri Resource Corporation (CRUCF) Income Statement Analysis – Financial Results
Complete financial analysis of Edoc Acquisition Corp. (ADOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edoc Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Centrais Elétricas Brasileiras S.A. – Eletrobrás (ELET6.SA) Income Statement Analysis – Financial Results
- Seplat Energy Plc (SEPL.L) Income Statement Analysis – Financial Results
- Wilmington Capital Management Inc. (WCM-A.TO) Income Statement Analysis – Financial Results
- Samyang Holdings Corporation (000070.KS) Income Statement Analysis – Financial Results
- OPG Power Ventures Plc (OPG.L) Income Statement Analysis – Financial Results
Edoc Acquisition Corp. (ADOC)
About Edoc Acquisition Corp.
Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.54M | 1.80M | 0.00 |
| Gross Profit | -2.54M | -1.80M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 1.80M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.54M | 1.80M | 89.34K |
| Other Expenses | 2.54M | -70.30K | -565.30K |
| Operating Expenses | 2.54M | 1.80M | -565.30K |
| Cost & Expenses | 2.54M | 1.80M | -565.30K |
| Interest Income | 314.16K | 20.87K | 8.68K |
| Interest Expense | 36.10K | 5.03K | 0.00 |
| Depreciation & Amortization | 2.54K | 1.80K | 268.02 |
| EBITDA | -5.14K | 898.22 | -1.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.54K | -1.80K | -268.02 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.14M | 898.22K | -1.43K |
| Income Before Tax | -7.69K | -899.88 | -1.70K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.14K | 898.22 | -1.43K |
| Net Income | -7.69K | -899.88 | -1.70K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 5.93M | 11.80M | 11.80M |
| Weighted Avg Shares Out (Dil) | 5.93M | 11.80M | 11.80M |
ADOCIA Announces Its Annual Results for 2022 and Provides Corporate and Financial Update
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its annual financial results...
ADOCIA : résultats annuels 2022 et bilan des activités et de la situation financière à date
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce aujourd'hui ses...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: ADOCIA (Paris:ADOC): Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA, 115, avenue Lacassagne, 69003 Lyon (Euronext...
Number of Shares and Voting Rights of ADOCIA as of January 31st, 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: ADOCIA (Paris:ADOC): Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA,...
Adocia Publishes Its Letter to Shareholders
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the January...
Adocia : Mise à Disposition de la Lettre aux Actionnaires
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce ce jour la...
ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets
LYON, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31st, 2022: Number of shares : 28,970 Cash balance of the liquidity account:...
ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec la société Kepler Capital Markets
LYON, France--(BUSINESS WIRE)--Regulatory News: Au titre du contrat de liquidité confié à Kepler Capital Markets portant sur les actions de la société ADOCIA (Paris:ADOC), les moyens suivants figuraient au compte de liquidité à la date du 31 décembre 2022 :...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, publie le nombre d’actions...
Number of Shares and Voting Rights of ADOCIA as of December 31st, 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, releases its total number of outstanding shares...
Source: https://incomestatements.info
Category: Stock Reports